STAT3 and hepatocellular carcinoma: Previous studies have also demonstrated that increased IL-6 in HCC activates the STAT3/c-MYC/miR-25-3p pathway, resulting in a decrease in protein tyrosine phosphatase receptor O (PTPRO), which downregulates PD-L1 expression by regulating JAK2-STAT1/3 activation (152).